logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12195517 B1

PDFFull Text
Date of Patent:
Jan. 14, 2025

Filed:

Jun. 12, 2019

Recombinant viral vector, immune composition containing same, and use thereof

Applicant:

Vacdiagn Biotechnology Co., Ltd, Suzhou, CN;

Inventors:

Jianqing Xu, Suzhou, CN;

Yang Huang, Suzhou, CN;

Xiaoyan Zhang, Suzhou, CN;

Lu Wang, Suzhou, CN;

Mingquan Gao, Suzhou, CN;

Jiahao Sun, Suzhou, CN;

Assignee:

VACDIAGN BIOTECHNOLOGY CO., LTD, Jiangsu, CN;

Attorney:

Christensen O'Connor Johnson Kindness PLLC

Primary Examiner:

Rachel B Gill

Int. Cl.
CPC ...
C07K 14/73 (2006.01); A61K 39/00 (2006.01); A61K 39/02 (2006.01); A61K 39/12 (2006.01); A61K 39/145 (2006.01); A61K 39/245 (2006.01); A61P 31/04 (2006.01); A61P 31/16 (2006.01); A61P 31/20 (2006.01); A61P 31/22 (2006.01); A61P 35/00 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70514 (2013.01); A61K 39/001184 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/107 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); A61K 39/245 (2013.01); A61P 31/04 (2018.01); A61P 31/16 (2018.01); A61P 31/20 (2018.01); A61P 31/22 (2018.01); A61P 35/00 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/53 (2013.01); A61K 2039/575 (2013.01); C07K 2319/00 (2013.01); C12N 2710/16122 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/24043 (2013.01); C12N 2760/16022 (2013.01); C12N 2760/16034 (2013.01);
Abstract

The present invention provides a recombinant viral vector, an immunogenic composition containing the same, and the use thereof. The recombinant viral vector comprises a polynucleotide encoding a fusion peptide of CD4 helper T cell epitopes, the epitope fusion peptide comprising a cytomegalovirus epitope and/or an influenza virus epitope. The epitope fusion peptide and the recombinant viral vector provided by the present invention can improve the level of cellular immune response to a target immunogen, particularly to a weak immunogen, and overcome the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen. The products of the present invention are suitable for enhancing the efficacy of vaccines.

Find Patent Forward Citations

Loading…